Kyle Kolaja
About Kyle Kolaja
Kyle Kolaja is the Scientific Vice President at Bristol Myers Squibb in Summit, New Jersey, with extensive experience in toxicology and cell therapy safety.
Current Role at Bristol Myers Squibb
Kyle Kolaja is currently serving as the Scientific Vice President at Bristol Myers Squibb in Summit, New Jersey. He leads the Development and Reproductive Toxicology, Genetic & Occupational Toxicology, and Immunotoxicology Groups. Additionally, he is responsible for the preclinical safety of the entire BMS cell therapy portfolio.
Previous Roles at Bristol Myers Squibb
Before his current role, Kyle Kolaja was the Executive Director of Investigative Toxicology and Therapy Area Head for Hematology/Cell Therapy Safety at Bristol Myers Squibb from 2019 to 2022. During his tenure, he played a significant role in overseeing toxicology assessments and safety operations.
Professional Experience at Celgene
From 2015 to 2019, Kyle Kolaja worked as a Senior Director at Celgene in Summit, NJ. His time at Celgene involved leading toxicology initiatives and contributing to the development of innovative therapies.
Educational Background
Kyle Kolaja earned his Ph.D. in Toxicology from Indiana University School of Medicine, where he studied under the mentorship of James Klaunig from 1992 to 1996. He completed his post-doctoral fellowship at the University of Kansas Medical Center from 1996 to 1998, under the mentorship of Curt Klaassen. He also holds a BS in Physiology from Michigan State University, which he obtained from 1988 to 1992.
Leadership in Professional Organizations
Kyle Kolaja has held prominent positions in several professional organizations. He served as the President of the Society of Toxicology's Specialty Sections for Drug Discovery Toxicology and Stem Cells and Toxicology. Additionally, he has been the Past President of the Academy of Toxicological Sciences and a Diplomate of the American Boards of Toxicology. He has also served on the Board of Directors for both the Academy of Toxicological Sciences and the American Boards of Toxicology.